Rob van Maanen
Chief Tech/Sci/R&D Officer at BIOPHYTIS S.A.
Net worth: 287 $ as of 31/03/2024
Profile
Rob van Maanen is currently the Chief Medical Officer at Biophytis SA since 2021.
Prior to this, he worked as the Senior Director-Medical at Astellas BV and as the Chief Medical Officer at Khondrion BV.
He holds an MBA from the University of Amsterdam and a doctorate from the University of Utrecht.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BIOPHYTIS SA
0.01% | 29/02/2024 | 75,983 ( 0.01% ) | 287 $ | 31/03/2024 |
Rob van Maanen active positions
| Companies | Position | Start |
|---|---|---|
| BIOPHYTIS S.A. | Chief Tech/Sci/R&D Officer | 09/09/2021 |
Former positions of Rob van Maanen
| Companies | Position | End |
|---|---|---|
Astellas BV
 Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The private company is based in Leiden, Netherlands. | Chief Tech/Sci/R&D Officer | - |
Khondrion BV
 Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Chief Tech/Sci/R&D Officer | - |
Training of Rob van Maanen
| University of Amsterdam | Masters Business Admin |
| University of Utrecht | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BIOPHYTIS S.A. | Health Technology |
| Private companies | 2 |
|---|---|
Astellas BV
Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The private company is based in Leiden, Netherlands. | Finance |
Khondrion BV
Khondrion BV Pharmaceuticals: MajorHealth Technology Khondrion BV is a Dutch clinical-stage biopharmaceutical company that focuses on discovering and developing therapies for mitochondrial diseases. The company is based in Nijmegen, Netherlands, and was founded in 2012 by Jan Smeitink, who has been the CEO since then. The company's lead drug candidate, sonlicromanol, is a first-in-class, oral small molecule that targets key underlying mechanisms of primary mitochondrial disease. The compound has been granted orphan drug designations for the treatment of various mitochondrial diseases. Khondrion collaborates with a clinical and academic network and patient organizations internationally to accelerate the discovery and development of its potential medicines. | Health Technology |
- Stock Market
- Insiders
- Rob van Maanen